Patent intelligence · US
US 11407712
Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2α
Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2α
Patent details — US 11407712
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 9, 2022
- Expiration
- Aug 4, 2042
- Applicant
- Arcus Biosciences, Inc.
- Claims
- 15
- CPC classes
- A61K, A61K31/10, A61K31/277, A61K31/343
Quick answer
US 11407712 (Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2α) is held by Arcus Biosciences, Inc.. Status: granted. Granted Aug 9, 2022. Expires Aug 4, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Arcus Biosciences, Inc.
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K31/10, A61K31/277, A61K31/343, A61K31/353, A61K31/365
More from Arcus Biosciences, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12415854
Antibodies to TIGIT
granted -
US 12410170
2,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine compounds
granted -
US 12384773
Thiazole compounds and methods of use thereof
granted -
US 12310965
Treatment of cancer utilizing an identified adenosine fingerprint
granted -
US 12281136
Crystalline forms of a CD73 inhibitor and uses thereof
granted -
US 12226425
Inhibitors of ARG1 and/or ARG2
granted -
US 12195447
Azolopyrimidine for the treatment of cancer-related disorders
granted -
US 12168023
Inhibitors of adenosine 5′-nucleotidase
granted
Frequently asked questions
What is US patent 11407712?
US 11407712 (Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2α) is held by Arcus Biosciences, Inc.. Status: granted. Granted Aug 9, 2022. Expires Aug 4, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11407712?
Arcus Biosciences, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 30 pharmaceutical patents for this assignee.
When does US 11407712 expire?
Our index shows an expiration date of Aug 4, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.